Elsevier

Toxicology

Volume 96, Issue 1, 19 January 1995, Pages 29-35
Toxicology

Agglutinating activity of wheat gliadin peptide fractions in coeliac disease

https://doi.org/10.1016/0300-483X(94)02912-EGet rights and content

Abstract

The K 562 (S) cell agglutinating activity of peptides obtained from in vitro digestion of bread wheat gliadins has been shown to be associated with a small fraction (coded as Fraction C), that can be easily separated by affinity chromatography of the whole digest on a sepharose 6-B-mannan or sepharose 6-B-oligomers of N-acetyl-glucosamine. Although the whole gliadin digests from 12 durum wheat varieties were unable to agglutinate K 562 (S) cells, all these digests were found to contain an active Fraction C. The lack of agglutinating activity of the whole durum wheat gliadin digests has been shown to be associated with the presence in these digests of another peptide fraction (coded as Fraction B) that is eluted much earlier from the sepharose 6-B-mannan column and is able to inhibit the cell agglutinating activity of Fraction C. Such an active Fraction B is not present in breadwheat gliadin peptides, although peptides with the same elution profile as Fraction B have been detected.

References (12)

There are more references available in the full text version of this article.

Cited by (23)

  • Next-generation therapies for celiac disease: The gluten-targeted approaches

    2018, Trends in Food Science and Technology
    Citation Excerpt :

    Beyond gluten-targeted therapies, others were developed aiming to manage the known mechanisms of mucosal damage in celiac disease. For example, decreasing intestinal permeability (Kelly et al., 2009; Paterson, Lammers, Arrieta, Fasano, & Meddings, 2007), inhibitors of TG2 activity (Choi et al., 2005; de Macédo, Marrano, & Keillor, 2002; Hausch, Halttunen, Mäki, & Khosla, 2003; Jeitner, Delikatny, Ahlqvist, Capper, & Cooper, 2005; Lai, Slaughter, Peoples, Hettasch, & Greenberg, 1998; Maiuri et al., 2005; Molberg et al., 2001; Pardin, Roy, Lubell, & Keillor, 2008), inhibition of gluten peptide presentation by HLA-DQ2 antagonists (Anderson, van Heel, Tye-Din, Jewell, & Hill, 2006; Bolin et al., 2000; Falcioni et al., 1999; Kapoerchan et al., 2008; Xia et al., 2007; Xia, Siegel, Bergseng, Sollid, & Khosla, 2006), gluten peptides that down-regulate the innate immune response (De Vincenzi, Dessi, Giovannini, Maialetti, & Mancini, 1995; De Vincenzi, Gasbarrini, & Silano, 1997; Silano et al., 2008; Silano, Di Benedetto, et al., 2007; Silano, Leonardi, et al., 2007) and immune modulation and induction of tolerance to gluten (Croese et al., 2015; Huibregtse et al., 2009; Keech, Dromey, Chen, Anderson, & McCluskey, 2009; Maurano et al., 2001; Medina, De Palma, Ribes-Koninckx, Calabuig, & Sanz, 2008; Rossi et al., 1999; Senger et al., 2003) were described. Additional therapies currently used or evaluated for other autoimmune diseases, such as rheumatoid arthritis and/or inflammatory bowel disease, are being studied for possible application in the treatment of refractory celiac disease (a condition very similar to celiac disease, but which cannot be relieved before at least 12 months of the gluten-free diet) and enteropathy-associated T-cell lymphoma (Schuppan, Junker, & Barisani, 2009).

  • Celiac Disease: From Pathogenesis to Novel Therapies

    2009, Gastroenterology
    Citation Excerpt :

    Of note, transglutaminase inhibitors based on a high affinity thiol binding group were recently developed that display 70- to 225-fold specificity for TG2 over TG1, TG3, TG6, and factor XIII when tested in vitro (Pasternack R, Hils M, Zedira Company, Darmstadt, Germany, personal communication, September 2009), raising hopes for increased safety of this approach. An “innate inhibitory” decapeptide (sequence QQPQDAVQPF) was isolated by affinity chromatography and gel filtration from durum wheat and tested in various in vitro systems.242–249 This peptide prevented agglutination of K562 erythroleukemic cells induced by PT-digested gliadin or α-gliadin p31-43243,245 and protected Caco2 intestinal epithelial cells from apoptosis induced by gliadin.246

View all citing articles on Scopus
View full text